Novavax, Inc. (NASDAQ:NVAX) is a vaccine company that is likely to have multiple milestones this year. It has U.S. government funding for seasonal and pandemic flu, and is developing its own products for respiratory syncytial virus (RSV). Novavax, Inc. (NASDAQ:NVAX) stock performance was -5.02% in last session and finished the day at $6.05. Traded volume was 4.36million shares in the last session and the average volume of the stock remained 5.27million shares. The beta of the stock remained 2.13. Novavax, Inc. (NASDAQ:NVAX) insider ownership is 0.10%.

It would be a gross understatement to say that Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) has gone through some aches and pains. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) dropped -5.51 percent to $3.43 yesterday on volume of 2.37 million shares. The intra-day range of the stock was $3.40 to $3.63. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has a market capitalization of $331.60million.

A $14,000 grant from Clorox Co. (NYSE:CLX) allowed the purchase of essentials, including stand mixers, mixing bowls, cookware and rolling carts. The Clorox Co (NYSE:CLX)’s stock on Mar 06, 2014 reported a increase of 0.08% to the closing price of $86.63. Its fifty two weeks range is $80.20 -$96.76. The total market capitalization recorded $11.25billion. The overall volume in the last trading session was 785.026million shares. In its share capital, The Clorox Co (NYSE:CLX) has 129.84million outstanding shares.

Halozyme Therapeutics, Inc. (NASDAQ:HALO), the $1.82 billion market capped biopharma company was a mover in the last session. On Wednesday, shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) dropped -6.57% to close the day at $14.22. Company return on investment (ROI) is -67.10% and its monthly performance is recorded as 3.19%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) quarterly revenue growth is -4.05%.